UNSPSC 51112028: Regorafenib

Regorafenib is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase.

UNSPSC 51112028 Regorafenib is a Commodity code that names a single pharmaceutical product — an oral tyrosine kinase inhibitor used in oncology treatment — yet the recent state and local opportunities block contains no solicitations actually procuring regorafenib or any other branded cancer therapeutics. Instead, the tagged opportunities span medical oxygen rentals, naloxone distribution, generic pharmaceuticals through cooperative purchasing, peer support services, clinic operations, and forensic drug standards, none of which align with the regorafenib code's nominal scope. The mismatch reflects a classification issue: state and local procurement systems occasionally tag opportunities with codes that do not match the work being solicited, and this code shows little recent relevant activity in the state and local market.

The single procurement that approaches pharmaceutical supply — the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026, with responses due March 26, 2026 — targets generic and over-the-counter inventory across state and local government facilities, not branded oncology drugs. The City of Tucson Fire Department's RFP 260305 for BLS/ALS pharmaceuticals and supplies (posted June 24, 2026) procures emergency medical inventory, not cancer therapeutics. Seminole County's ITQ for naloxone and drug deactivation systems (posted June 30, 2026, due July 26, 2023) addresses overdose response, not oncology. The code does not appear in recent state or local contract notices as a driver for active procurement, and issuing bodies across Florida, Texas, Arizona, Minnesota, and Arkansas show no pattern of buying regorafenib or similar specialty oncology agents under this classification.